Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Medical Devices

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Revenue projections:

Revenue projections for ZBH
Revenue projections for ZBH

ZBH's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.

Financial Ratios:

currentRatio 1.691000
forwardPE 10.934947
debtToEquity 60.175000
earningsGrowth 0.338000
revenueGrowth 0.048000
grossMargins 0.698770
operatingMargins 0.179600
trailingEps 4.120000
forwardEps 9.067260

ZBH's current ratio being 1.691 suggests the company will have no issues paying off its short-term debt. With sufficient cash reserves and current assets, ZBH can easily cover its immediate liabilities, reflecting solid financial health.
ZBH's Forward PE is in a favorable range, meaning its stock price compares well with its earnings and isn't overpriced. This leaves room for growth, making it a compelling opportunity for investors looking to benefit from potential future gains.
ZBH's forward EPS is higher than its trailing EPS, which signals that the company is expected to achieve greater profitability this financial year. This suggests improved earnings performance, indicating a positive outlook for ZBH's financial growth.

Price projections:

Price projections for ZBH
Price projections for ZBH

ZBH's stock price has regularly been near the lower end of projections, indicating that it may be struggling to attract investor interest. This pattern suggests a cautious sentiment surrounding the company's future performance.

Insider Transactions:

Insider Transactions for ZBH
Insider Transactions for ZBH


8 ZBH transactions were recorded, when the market price was 95.86240482330322.During the period under review, no sell transactions were recorded.The recent trend of increased buying at ZBH's current price levels may indicate a favorable market sentiment. This could point to a positive outlook for the stock, as investors show growing confidence through higher buy activity.

Recommendation changes over time:

Recommendations trend for ZBH
Recommendations trend for ZBH


The recent buy bias from analysts suggests Zimmer Biomet Holdings, Inc. is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, Zimmer Biomet Holdings, Inc. appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.